Abstract：
Antipsychotics (APs) have been increasingly prescribed for psychiatric disorders from schizophrenia to disruptive behavioral conditions. These drugs have been associated with considerable side effects, such as weight gain, and increasing evidence has also indicated that its use impacts gut microbiota (GM), although this connection is still little understood. To assess APs effects on the GM of patients starting or ongoing treatment, a systematic review was carried out in PubMed and Scopus databases. Twelve articles were considered eligible for the review, which investigated the effects of risperidone (5 studies), quetiapine (3), amilsupride (1), olanzapine (1), and unspecified atypical drugs (2). Eleven reported changes in GM in response to APs, and associations between the abundance of bacterial groups and different metabolic parameters were described by most of them. However, the studies were noticeably heterogeneous considering design, methods, and results. In this way, the effects of APs on GM composition and diversity were inconclusive. Despite the uncertain interactions, a more comprehensive understanding on how microbiota is affected by APs may help to optimize treatment, potentially minimizing side effects and improving adherence to treatment.
摘要：
抗精神病药（AP）已越来越多地用于从精神分裂症到破坏性行为条件的精神疾病。这些药物有相当大的副作用，比如体重增加，越来越多的证据也表明，它的使用会影响肠道微生物群(GM)，虽然这种联系仍然很少被理解。为了评估AP对开始或正在进行治疗的患者的GM的影响，在PubMed和Scopus数据库中进行了系统评价.12篇文章被认为有资格接受审查，调查了利培酮的作用(5项研究)，喹硫平（3），amilsupride(1),奥氮平（1），和未指明的非典型药物（2）。11个报告了GM响应AP的变化，大多数细菌描述了细菌群的丰度与不同代谢参数之间的关联。然而,考虑到设计，这些研究明显是异质的，方法,和结果。这样,AP对GM组成和多样性的影响尚无定论。尽管存在不确定的相互作用，更全面地了解微生物群如何受到AP的影响可能有助于优化治疗，可能最大限度地减少副作用并提高对治疗的依从性。
